Singapore-based venture firm Seveno Capital has announced a strategic investment in Hong Kong healthtech startup PointFit, valuing the company at US$10 million and signalling rising investor confidence in next-generation wearable technologies that move beyond heart-rate tracking.
PointFit, incubated at the Hong Kong University of Science and Technology, is developing a skin patch wearable designed for non-invasive, real-time biomarker monitoring through sweat. Its first product focuses on Continuous Lactate Monitoring (CLM), enabling users to track fatigue, endurance and recovery without invasive blood tests or laboratory analysis.
The company’s approach marks a shift in the wearable technology landscape, moving from devices that infer physiological states through proxies such as heart rate and motion, toward direct biological measurement captured at the skin. While biomarker tracking has traditionally been confined to elite sports and clinical research settings due to invasive and controlled testing environments, PointFit aims to translate laboratory-grade insight into an accessible wearable format.
Although its initial focus is endurance biomarkers — including lactate, electrolytes and sweat rate — PointFit is building a modular platform capable of expanding into broader diagnostic applications spanning performance optimisation, metabolic health and longevity-focused care.
Industry analysts project the global wearable market will reach a total addressable market of US$200 billion by 2030, driven by consumer demand for clinical-grade biological data rather than basic activity tracking. Within this broader opportunity, PointFit is targeting an estimated US$15 billion serviceable addressable market comprising tens of millions of dedicated endurance athletes seeking real-time physiological optimisation.
The startup has conducted demonstrations with global sports federations, professional teams, retailers and fitness equipment manufacturers. As it enters commercialisation, Seveno Capital plans to support its integration with international stakeholders, particularly in North America. Recent product showcases in Indiana and participation in the Startup World Cup Finale in Silicon Valley have strengthened its engagement with the US sports and venture ecosystem. PointFit is also backed by Creative Destruction Lab, a science-based global accelerator supporting high-growth ventures.
The company’s international profile rose further at CES 2026 in Las Vegas, where it received a CES Innovation Award in Digital Health, positioning it among closely watched emerging sports technology firms in the United States.
Seveno Capital views the investment as part of a broader shift in the global fitness and wellness sector increasingly influenced by Asian innovation and capital. A recent example is Anta Sports’ acquisition of a 29 per cent stake in Puma in January 2026, a move widely seen as a signal of cross-border consolidation driven from Asia.
The PointFit deal is Seveno Capital’s first transaction since opening its Hong Kong office, which will serve as a base for sourcing and scaling globally relevant technologies at the intersection of performance, prevention and longevity. The investment is also the inaugural deal led by Jean-Baptiste Roy, who recently joined the firm as Partner to expand its international scope and deepen its focus on performance-led, data-driven platforms.
Allen Law, Principal at Seveno Capital, said the firm backs technologies capable of defining new global categories in preventive health. Roy added that Hong Kong offers strategic access to Asia while enabling international scale.
Kenny Oktavius, Co-Founder and CEO of PointFit, said the partnership aligns with the company’s belief that healthcare’s future lies in preventive and personalised approaches. With Seveno’s global network across Asia, Europe and the Middle East, he said PointFit aims to accelerate the rollout of its PF-Sweat Patch from elite sports into broader consumer markets.
The investment underscores growing momentum behind wearable platforms that promise continuous, real-time biological insight, a development investors increasingly view as central to the next phase of healthspan innovation.